News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-04-24 pm EDT			5-day change	1st Jan Change
7.370 ^USD	+1.10%		-3.53%	-46.24%

Apr. 21	Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing	CI
Apr. 09	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing	Apr. 21	GL
Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing	Apr. 21	CI
Guggenheim Downgrades Myriad Genetics to Neutral From Buy	Apr. 09	MT
Myriad Genetics Announces Inducement Awards	Apr. 08	GL
Myriad Genetics Announces Inducement Awards	Apr. 08	AQ
Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer	Apr. 07	RE
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer	Apr. 07	GL
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer	Apr. 07	AQ
Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025	Apr. 07	CI
Sector Update: Health Care Stocks Lower Late Afternoon	Mar. 12	MT
Myriad Genetics Shares Rise After Upgrade From Piper Sandler	Mar. 12	MT
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	Mar. 12	MT
Myriad Genetics And Gabbi To Work Together To Increase Access To Hereditary Cancer Risk Assessment Tools	Feb. 27	RE
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools	Feb. 27	GL
Myriad Genetics, Inc. Provides Financial Guidance for 2025	Feb. 26	CI
UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	Feb. 25	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Underwhelming Economic Data, Renewed Trade Tensions	Feb. 25	MT
Myriad Genetics Appoints Sam Raha as Chief Executive	Feb. 25	MT
Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated	Feb. 25	MT
Myriad: Q4 Earnings Snapshot	Feb. 24	AQ
Myriad Genetics Appoints Sam Raha As President And CEO	Feb. 24	RE
Myriad Genetics, Inc., Q4 2024 Earnings Call, Feb 24, 2025	Feb. 24
Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Fourth Quarter Ended December 31, 2024	Feb. 24	CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 24	CI
Earnings Flash (MYGN) Myriad Genetics, Reports Q4 Revenue $210.6M, vs. FactSet Est of $211.6M	Feb. 24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Filters